<DOC>
	<DOCNO>NCT01981278</DOCNO>
	<brief_summary>The purpose study evaluate bioequivalence ( scientific basis drug active ingredient ( ) compare ) new tapentadol extended-release ( ER ) 250-mg tamper-resistant formulation ( TRF ) tablet current tapentadol ER 250-mg prolonged-release formulation 2 ( PR2 ) tablet healthy participant fast condition .</brief_summary>
	<brief_title>A Study Assess Bioequivalence New Tapentadol Extended-Release 250-mg Tablet With Respect Tapentadol Extended-Release 250-mg Tablet Healthy Participants</brief_title>
	<detailed_description>This open-label ( people know identity intervention ) , single-center , randomize ( study medication assign chance ) , 2-way crossover ( method use switch participant one treatment arm another clinical study ) study single dose 250-mg tapentadol . All participant receive randomize order TRF tablet PR2 tablet , single dose 250 mg tapentadol . Approximately 64 participant enrol study . The study consist 3 phase : screening phase ( within 2 21 day first study drug administration Day 1 Period 1 ) , open-label treatment phase consist 2 single-dose treatment period . Treatment administration separate washout period 7 14 day . All participant randomly assign 1 2 possible treatment sequence receive follow treatment , 1 period : Treatment A : tapentadol ER 250-mg TRF tablet , administer single oral dose fast condition Treatment B : tapentadol ER 250-mg PR2 tablet , administer single oral dose fast condition . Safety evaluate assessment adverse event , vital sign , physical examination , 12-lead electrocardiogram , clinical laboratory test monitor throughout study . The duration participation study individual participant 5.5 week .</detailed_description>
	<criteria>Signed informed consent document indicate understand purpose procedure require study , willing participate study , willing adhere prohibition restriction specify protocol Healthy basis prestudy physical examination , medical history , 12lead electrocardiogram , vital sign , clinical laboratory parameter perform within 21 day study drug administration Women must negative serum human chorionic gonadotropin ( hCG ) pregnancy test screen Day 1 treatment period Must agree use adequate contraception method donate sperm study 3 month receive last dose study medication Body mass index ( BMI ) ( weight [ kg ] /height [ m2 ] ) 20 28 kg/m2 , inclusive , body weight less 50 kg History seizure disorder epilepsy mild moderate traumatic brain injury , stroke , transient ischemic attack , brain neoplasm within 1 year screening , severe traumatic brain injury within 15 year screen , severe traumatic brain injury result ongoing sequela suggest transient change consciousness symptom History gastrointestinal disease affect absorption , gastric surgery history current significant medical illness include cardiac arrhythmia cardiac disease , hematologic disease , coagulation disorder , lipid abnormality , significant pulmonary disease , diabetes mellitus , renal hepatic insufficiency , thyroid disease , neurologic psychiatric disease , infection History clinically significant allergy , especially know hypersensitivity/intolerance contraindication opioids , opioid antagonist ( eg , naloxone ) , benzodiazepine ( eg , diazepam , clonazepam , lorazepam ) , study drug formulation component , excipients formulation , heparin Women plan become pregnant study , breastfeed Positive test human immunodeficiency virus ( HIV ) antibody , hepatitis B surface antigen ( HBsAg ) , hepatitis C antibody</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Healthy</keyword>
	<keyword>Tapentadol</keyword>
	<keyword>Bioequivalence</keyword>
	<keyword>Fasted</keyword>
</DOC>